MedTrace Logo

IV Iron-induced Hypophosphatemia After RYGB

NCT06350955 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2024-08-20

No results posted yet for this study

Summary

The primary objective of the study is to compare the incidence of hypophosphatemia in RYGB patients treated with intravenous (IV) single dose of iron isomaltoside (Monofer®) or ferric carboxymaltose (Ferinject®).

Conditions

  • Hypophosphatemia
  • Roux-en-Y Gastric Bypass

Interventions

DRUG

Iron isomaltoside

single dose of 500 mg iron isomaltoside

DRUG

Iron Carboxymaltose

single dose of 500 mg ferric carboxymaltose

Sponsors & Collaborators

  • Lucie Favre

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-02
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06350955 on ClinicalTrials.gov